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Purpose: To evaluate the efficacy of intrauterine Bakri balloon tamponade as a management of 
massive postpartum hemorrhage (PPH).
Methods: Retrospective study including women who underwent intrauterine Bakri balloon tam­
ponade for massive PPH between April 2010 and July 2015 was conducted. Massive PPH was 
defined as estimated blood loss exceeding 1,500 mL. Bakri balloon was inserted into uterus if wo­
men had PPH despite medical treatment after vaginal delivery or cesarean section. The balloon was 
inflated with sterile saline and removed after 12­24 hours. Failure was defined as needing another 
procedure for hemorrhage control. Demographic, obstetric and specific factors in regard to the Bakri 
balloon use were recorded. The successful rate of hemostasis by Bakri balloon was evaluated. 
Results: Among 138 women with PPH managed Bakri balloon insertion, 57 patients were dia­
gnosed with massive PPH. The most common cause of massive PPH was placenta previa without 
accreta (54.4%), uterine atony (33.3%), placenta previa with accreta (10.5%) and placenta accreta 
(1.8%). The mean estimated blood loss was 2279.0 mL (range, 1,500­6,500 mL). The rate of success­
ful control of massive PPH after Bakri balloon placement was 82.5%. From the cases of 57 patients, 
10 patients needed additional procedures; five required uterine artery embolization and five under­
went cesarean hysterectomy. No short­term complications or maternal death were observed after 
Bakri balloon insertion. 
Conclusion: Bakri balloon tamponade is an effective, simple and quick approach in the treatment 
of massive PPH and it is useful as complementary management for earning time for another 
procedure. 
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Introduction
Postpartum hemorrhage (PPH) is a life-threatening complication in obstetrics and it 
is a major cause of maternal mortality worldwide.
1
 PPH has been traditionally defined 
as an estimated blood loss of more than 500 mL after vaginal delivery or over 1,000 
mL after cesarean section. Particularly if woman has massive PPH which is defined as 
bleeding exceeding 1,500 mL during delivery, patient may be in danger with needing 
massive transfusion, critical care and increasing the risk of death.
2
 The main causes of 
PPH are uterine atony, genital tract laceration, abnormal placentation, retained placental 
products and coagulation abnormalities, The management of PPH differs depending 
on these etiologies. The primary treatments for PPH include treatment of uterine atony 
with uterotonic agents, bimanual uterine massage and blood product replacement. If 
these conservative managements fail, surgical interventions must be considered. Surgical 
methods consist of ligation of uterine artery, intrauterine compression sutures and 
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hysterectomy. Postpartum hysterectomy causes increased 
blood loss, injury to other organs and irreversible loss of fer-
tility. Therefore, other nonsurgical conservative methods 
such as uterine artery embolization (UAE) or uterine balloon 
tamponade should be considered before hysterectomy. 
Intrauterine balloon tamponade has been quite widely 
used as a second-line procedure in the management of PPH. 
This tool acts to stop uterine bleeding via increasing in-
trauterine pressure over systemic pressure around the pla-
cental bed or low segment in placenta previa.
3
 Different 
balloons have been used such as the Sengstaken-Blakemore 
tube, Foley, Rusch or Bari balloon. The success rate for this 
technique has been reported by 60-90%.
4-7
 Among these 
balloons, the Bakri balloon is specifically designed to fit into 
the uterine cavity, and it has been used popularly due to 
simple management and easy access. 
This study describes the use of Bakri balloon for mana-
ging massive PPH that bleeding more than 1,500 mL after 
delivery. The aim of this study was to evaluate the success 
rate of Bakri balloon in cases of massive PPH that were 
intractable to medical treatment. 
Materials and methods
This study was a retrospective review of patients diagnos-
ed with massive PPH who failed conservative management 
with uterotonic agents and were subsequently treated with 
intrauterine balloon tamponade at one institute between 
April 2010 and July 2015. This study was approved by the 
Institutional Review Board of Severance Hospital. Medical 
records were reviewed to gather demographic, obstetric and 
specific factors involved in the use of balloon tamponade. 
Massive PPH was defined as >1,500 mL estimated blood 
loss after vaginal delivery or cesarean section. This was 
measured of the amount of bleeding before Bakri balloon 
insertion. The first standard managements for PPH such 
as uterine massage, bimanual compression, or medication 
with an intravenous infusion of Oxytocin (20-40 IU in 1,000 
ml Ringer's lactate solution at a rate of 120 mL/hour) or an 
additional injection of intravenous Carbetocin were applied 
to all patients. Close inspection of the cervix and vagina 
was performed routinely for distinguishing genital tract 
lacerations in women with profuse bleeding after vaginal 
delivery. Any patients with bleeding who need surgical 
procedure after vaginal delivery due to lower genital tract 
lacerations were excluded. If the bleeding continued despite 
of primary medical treatments, the Bakri balloon catheter 
(Bakri SOS balloon; Cook
®
 woman’s Health, Spencer, IN, US) 
was applied. 
The procedure for insertion of the Bakri balloon was 
similar to that originally described by the inventor.
8 
Follow-
ing vaginal delivery, the Bakri balloon was inserted trans-
vaginally under ultrasound guidance to confirm the correct 
positioning of the balloon. When the balloon was inserted 
during a cesarean section, the distal end of the catheter shaft 
was introduced into the uterine incision and passed through 
the cervix. After the balloon was inflated with approximately 
100 mL of sterile saline solution, the lower segment incision 
was closed carefully in order to avoid damaging the balloon. 
Further filling was depending on the size and capacity of 
the uterus. Then, Betadine-soaked gauzes were packed 
into vagina to prevent slippage or prolapse of the balloon 
through the cervix. The distal end of the catheter was fixed 
to the patient’s thigh and ultrasound visualization of balloon 
placement was confirmed after procedure. After Bakri bal-
loon placement, the balloon drainage end was connected to 
a collecting bag to monitor blood loss. The balloon remained 
in place between 12 and 24 hours. Removal of the catheter 
was by either complete deflation after 24 hours or stepwise 
deflation by removing 50% of the fluid at 12 hours followed 
by complete deflation after 12 hours.
Bakri balloon tamponade was considered to be failed if 
the bleeding from drainage catheter was continued and 
more than 100 mL during 10 minutes, so further interven-
tions such as UAE, compression sutures or hysterectomy 
were needed.  Women were hospitalized either in postnatal 
word or intensive care in the postpartum period depending 
on the level of PPH and maternal tolerance. Pain was 
evaluat ed using the Wong-Baker Faces Pain Rating Scale 
(FPS) before removal of the balloon tube. FPS is a series of 
facial expres sions to illustrate a spectrum of pain intensity.
9 
Research assistants pointed to each of the six faces and 
described each face using the brief word instructions pro-
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(1.8%). The mean estimated blood loss was 2,279 mL (range 
1,500-6,500 mL) before insertion of a Bakri balloon, and 20 
patients had a massive bleeding more than 2,500 mL. The 
mean volume of saline used to inflate balloon was 233.5 
mL (range 50-700 mL). None of the patients had the Bakri 
vided with the scale. Patients were asked to circle the face 
that best re presented their level of pain severity. All pa­
tients had a Foley catheter for urine output monitoring and 
prophylactic broad-spectrum antibiotics were used. We 
compared between Bakri balloon success group and failure 
group to identify factors associated with its failure, as well as 
determine if any complications were associated with its use. 
Outcome measures were compared with Student’s t-test 
and chi-square analysis, as well as Fisher’s exact test and 
Wilcoxon’s test when appropriate due to smaller sample 
size. A P value of 0.05 or below was considered statistically 
significant. 
Results
During the study period, 138 women who were diagnosed 
with PPH following either vaginal delivery or cesarean sec-
tion were managed with Bakri balloon. A total of 57 (41.3%) 
of these women had massive PPH with an estimated blood 
loss exceeding 1,500 mL. All patients were diagnosed massive 
PPH and treated during hospital stay except one case. In one 
case, massive PPH was occurred 6 days after she was dis-
charged from the hospital. She had cesarean section because 
of twin pregnancy. The mean age of these women were 
34.2 years and 28 (49.1%) were more than 35 years old. Of 
the women in whom the Bakri balloon was used for the 
management of massive PPH, twenty-three were nulliparous 
(40.4%) and three (5.3%) were multiple gestations (all were 
twin pregnancies). A total of 9 women (15.8%) delivered 
vaginally and 48 (84.2%) had a cesarean section. Out of 48 
women with cesarean section, Bakri balloon was inserted 
during operation in 45 women, at recovery room in 2 wo men 
and at emergency room in one women who had massive 
bleeding after discharge from hospital. The mean gestational 
weeks at the time of delivery was 37.7 (range 34.28-40.71). 
Mean weight of newborn was 3,006.9 g and 4 babies were 
diagnosed with large for gestational age (Table 1). 
As shown in Table 1, the leading cause of PPH was pla-
centa previa without accreta in 31 cases (54.4%), followed 
by uterine atony in 19 cases (33.3%), placenta previa with 
accreta in 6 cases (10.5%) and placenta accreta in 1 case 
Table 1. Baseline and Pregnancy-Associated Characteristics of Women 
with Bakri Balloon Tamponade
Characteristic N=57 (%)
Age, year (mean) 34.2 (range 25­41)
≥ 35 28 (49.1)
Parity
 0 23 (40.4)
 1 24 (42.1)
 ≥2 10 (17.5)
Multiple gestations 3 (5.3)
Mode of delivery
 Vaginal delivery 9 (15.8)
 Cesarean section
Elective 34 (59.6)
Emergency 14 (24.6)
Gestational age, weeks (mean) 37.7 (range 34.28­40.71)
Birthweight, g (mean) 3,006.9 (range 1,790­3,990)
 LGA 4 (7.0)
Blood loss, mL* (mean) 2,279.0 (range 1,500­6,500)
Volume of balloon inflation (mL) 233.5 (range 50­700)
Bakri balloon inflation time (hr) 17.1 (range 0.2­36.1)
Indication for Barki balloon tamponade
Uterine atony 19 (33.3)
Placenta previa without placenta accreta 31 (54.4)
Placenta previa with placenta accreta 6 (10.5)
Placenta accreta 1 (1.8)
Pain by FPS 3.7 (range 1­8)
ICU admission 20 (35.1)
Hemoglobin/Hematocrit, mg/dL/% (mean) 
Antepartum 11.2 (range 6.3­13.1)/
33.5 (range 19.4­40.1)
Postpartum† 9.1 (range 5.9­12.3)/
26.8 (range 16.5­36.3)
Day of postpartum admission, day (mean) 4.8 (range 2­12) 
Maternal death 0
Values are presented as mean (range) or n (%).
Abbreviations: LGA, large for gestational age; ICU, intensive care unit.
*Blood loss before Bakri balloon insertion.
†48hours after delivery.
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livered vaginally and three who delivered by cesarean sec-
tion underwent UAE; five women who delivered by cesa-
rean section underwent postpartum hysterectomy. In three 
cases of five patients with postpartum hysterectomy were 
diagnosed placenta accreta pathologically and in one case 
with UAE was suspected placenta accreta at the operation 
room. 
Maternal demographics showed no significant differences 
between success group and failures, with maternal age, 
gestational age, delivery mode and infants with large for 
gestational age (Table 3). The cause of massive PPH was 
not predictive of failure. There was no difference in vol-
ume of balloon inflation between two groups. Outcomes in 
balloon ruptured during and after inflation. The balloon was 
left in situ for 17.1 hours on average (range 0.2-36.1 hours). 
In 14 cases the balloon was in place less than 12 hours and 
in 9 cases more than 24 hours. Twenty patients were ad-
mitted to the intensive care unit for close monitoring. The 
mean pain score according to the FPS during Bakri balloon 
indwelling was 3.7 (range 1-8). 
The Bakri balloon tamponade was effective in 82.5% of 
the included women. In 57 cases, 47 women were success-
fully managed with Bakri balloon and no further sur gical 
interventions or UAE were needed. Ten of the 57 cases re-
quired additional treatment after failure of Bakri balloon 
tamponade management (Table 2). Two women who de-
Table 2. Additional Procedures Used in Eleven Cases with Bakri Balloon Tamponade Failure
Case Cause of PPH Mode of delivery
Gestational weeks 
at delivery Risk factors Procedure
Blood loss, 
mL
Transfusion, 
units
1 Placenta previa and accreta Elective CS 37.71 Placenta previa Hysterectomy 1,900 21 PBCs
4 FFP
6 Plt.conc
2 Placenta previa Elective CS 37.57 Placenta previa Hysterectomy 2,000 6 PBCs
1 FFP
5 Plt.conc
3 Uterine atony Elective CS 37.14 Multiple pregnancy,
Placenta previa
UAE 2,100 11 PBCs
3 FFP
8 Plt.conc
4 Placenta previa and accreta Elective CS 37.86 Placenta previa, two prior CS Hysterectomy 2,750 24 PBCs
4 FFP
12 Plt.conc
5 Placenta previa and accreta Elective CS 38.14 two prior curettages, placenta previa UAE 2,800 10 PBCs
5 FFP
6 Placenta previa and accreta Elective CS 37.71 Placenta previa Hysterectomy 3,000 6 PBCs
5 FFP
6 Plt.conc
7 Uterine atony VD 37.28 UAE 3,100 14 PBCs
5 FFP
8 Uterine atony VD 40.14 Large fetus UAE 3,800 28 PBCs
6 FFP
16 Plt.conc 
9 Placenta previa Emergency CS 37.14 Placenta previa UAE 2,300 13 PBCs
3 FFP
12 Plt.conc
10 Uterine atony Elective CS 38.28 Placenta previa Hysterectomy 3,500 10 PBCs
2 FFP
12 Plt.conc
Abbreviations: VD, vaginal delivery; CS, cesarean section; UAE, uterine artery embolization; PBC, packed blood cell; FFP, fresh frozen plasma; Plt.conc, Platelet concentrate.
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the failure group were notable for longer length of hospi-
talization, higher likelihood of ICU admission, and higher 
transfusion rate. The drained blood loss after Bakri insertion 
and average blood loss per 1 hour were heavier in the 
failure group compared to those of success group. 
No cases of hypoxic encephalopathy or death were en-
countered and no complications were observed due to in-
sertion of Bakri balloon such as uterine rupture, endo metritis 
and uterine incision dehiscence. 
Discussion
The incidence of PPH is steadily rising in association with 
an increased incidence of cesarean section with abnormal 
placentation, increased rates of maternal obesity and rising 
frequency of multiple pregnancies by artificial reproductive 
technologies.
10
 PPH is a significant cause of maternal mor-
bidity and mortality. Especially if massive, women suffer 
from acute renal necrosis, irreversible hypovolemic shock, 
disseminated intravascular coagulation, Sheehan’s syndrome 
until the death of the patient and death as well as severe 
anemia with the need for massive transfusion.
2
 Because late 
diagnosis and delayed management contribute to increased 
maternal morbidity when women had a massive PPH, rapid 
decision and interventions are essential. As a treatment for 
PPH, intrauterine balloon tamponade does not require either 
a highly technological facility or technical skill so that it can 
Table 3. Maternal Demographics and Outcomes between Success and Failure Group with Bakri Balloon Management
      Success (n=47)         Failure (n=10)   P value
Maternal age, yr 33.9 (range, 25­41) 35.3 (range, 31­39) 0.32
AMA 22 (46.8) 6 (60.0) 0.50
GA, wks 37.6 (range, 34.2­40.7) 37.9 (range, 37.1­40.1) 0.54
Delivery mode 0.65
Vaginal delivery 7(14.9) 2 (20.0)
Cesarean section 40 (85.1) 8 (80.0)
LGA 4(8.5) 1(11.1) 0.17
Cause of PPH 0.25
Uterine atony 15 (31.9) 4 (40.0)
Placenta previa without accreta 28 (59.6) 3 (30.0)
Placenta previa with accreta 3 (6.4) 3 (30.0)
Placenta accreta 1 (2.1) 1 (10.0)
Volume of balloon inflation 230.1 (range,50­700) 251.1 (range, 150­350) 0.23
Time between bleeding/balloon insertion (min) 48.1 (range, 2­350) 76.0 (range, 2­258) 0.44
Bakri balloon indwelling time (hr) 19.5 (range, 1.0­36.0) 5.0 (range, 0.16­27.0) <0.01
Drained blood loss   after Bakri insertion <0.01
Total 155.1 (range,0­560) 811.1 (range, 400­1200)
Per 1 hour 24.7 (range,0­400) 440.2 (range, 31.48­1195.6)
Blood loss* 2184.1 (range, 1500­6500) 2725.0 (range, 1900­3800) <0.01
Length of hospitalization 4.3 7.2 <0.01
ICU admissions 10 (21.3) 10 (100.0) <0.01
Transfusion 40 (85.1) 10 (100.0) 0.19
Hemoglobin, decreased 2.1 (range, ­1.7­4.9) 2.2 (range, ­0.7­4.7) 0.92
Hct, decreased 6.8 (range, ­3.5­16.4) 7.6 (range, ­2.6­14.1) 0.62
Values are presented as mean (range) or n (%).
Abbreviations: AMA, advanced maternal age (>35yr); GA, gestational age; LGA, large for gestational age; PPH, postpartum hemorrhage; ICU, intensive care unit
*Blood loss before bakri balloon insertion.
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be rapidly applied for hemostasis. This procedure is the 
least invasive and lower-cost approach and it can preserve 
fertility by preventing hysterectomy.  
The overall success rate of Bakri balloon in our study was 
82.5% which is comparable to previous studies. However, 
only few case series regarding outcomes using intrauterine 
balloon tamponade for massive PPH have been reported 
previously (Table 4). A series of 11 cases using Sengstaken-
Blakemore tubes was published, in which mean blood loss 
was 2000ml and 81.8% success rate.
11
 In another study using 
the Rusch balloon, the success rate 59.1% (13/22 cases) and 
seven patients need hysterectomy.
12
 Ferranzzani and col-
leagues reported that the Rusch balloon was successful in 
39 of the 52 cases (75.0%) without using other procedure for 
treatment of PPH.
13
 For the Bakri balloon, the rate of success 
varies from 84% (37/44 cases) in the study by Gronvall et 
al.,
14
 to 60% in that by Diemert et al.
15
 (12/20 cases), to 88% 
(55/61 cases) in the study by Alouini et al.
16
 In agreement 
with other studies, intrauterine balloon tamponade is effec-
tive for PPH even if massive bleeding during delivery.
In our study, both total drained blood loss and blood 
loss per hour after Bakri insertion were significant higher 
in failure group compared of those in success group, sug-
gesting that another procedure such as UAE or hysterec-
tomy should be considered when bleeding passed through 
drainage tube was over 400 mL within 1 hour. As continu ed 
bleeding after balloon insertion represent balloon manage-
ment failure, the Bakri balloon can make a rapid decision 
for another procedures such as UAE or surgical procedure 
when persisting bleeding was observed by connected tube. 
Although many series about the successful use of different 
types of balloon tamponades such as the Foley catheters, 
Sengstaken-Blakemore tubes and Rusch balloon catheters, 
these have many shortcomings.
17
 The balloon capacity of 
the Foley catheter is too small to result in satisfactory com-
pression of the uterus. The Sengstaken-Blakemore tube was 
originally designed for upper gastrointestinal tract bleeding. 
Thus, it does not conform to the shape of the uterus, and 
multiple ports often confuse the user at times of emergent 
use. As for the Rusch balloon catheter, there is a tendency 
to miss concealed hemorrhages due to the absence of a 
drainage port. The Bakri balloon catheter has been able to 
overcome these aforementioned limitations. This catheter 
was specifically designed to fit into the uterine cavity and is 
equipped with a drainage port for ongoing blood loss. 
The original Bakri balloon was used for low-lying pla-
centa/placenta previa
8
 and the Royal College of Obstetri-
cians and Gynaecologists (RCOG) guidelines of 2011 con-
sidered the intrauterine balloon for management of massive 
hemorrhage with placenta previa and accreta.
18
 In our study, 
the success rate of the use of Bakri balloon in massive PPH 
with placenta previa was 83.7% (31/37). If we consider 
that study group consisted of women with placenta previa 
without accreta, then our study showed a 90.3% success 
rate (28/31). Placenta previa and accreta are becoming more 
frequent as increasing rate of cesarean section and the 
association of uterine atony with abnormal placentation 
seems to be related with higher blood loss and more trans-
fusions. For these reasons, we suggest the Bakri balloon 
as an alternative treatment, which can be used to resolve 
massive PPH in cases of abnormal insertion of the placenta 
and before more invasive procedures. 
Table 4. Studies Reporting Uterine Balloon Tamponade Results with Severe postpartum hemorrhage
Authors Year Balloon type Mean blood loss (mL) No. of cases No. of successful cases Success rate (%) Postpartum hysterectomy
Majumdar A et al.12 2010 Rusch 2,450 22 13 59.1 7
Gronvall M et al.14 2012 Bakri 4,812 44 37 84.0 4
Diemert A et al.15 2012 Bakri 20 12 60
Chan LL et al.11 2013 SB 2,000 11 9 81.8 2
Ferranzzani S, et al.13 2014 Rusch 1,759 52 39 75.0 10
Alouini S16 2015 Bakri 1,600 61 55 88 6
Total 210 171 81.4
Abbreviation: SB, Sengstaken­Blakemore tubes.
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Among the 57 cases examined, ten required additional 
treatment after Bakri balloon tamponade. In five failed 
cases in the cesarean section group who later underwent 
hysterectomy, three had placenta previa with accreta. In 
one cases with cesarean section who had a successful Bakri 
balloon catheter placement during cesarean section for PPH 
due to placenta previa, massive rebleeding was noted in 
the recovery room caused by complete displacement of the 
balloon into the vaginal cavity. At the time of balloon place-
ment, the cervix was dilated to 1 cm but firm; therefore, 
vaginal gauze packing was not performed. However, results 
of a pelvic exam following balloon displacement showed 
that the cervix was dilated to 5-6 cm and 50% effaced. This 
finding led us to believe that the inflated balloon functioned 
as a transcervical catheter that mechanically dilated the cervix 
and a lack of balloon support (vaginal packing) contributed 
to balloon expulsion. Thus, we strongly recommend vaginal 
packing for balloon support and checking the balloon po-
sition by ultrasound at the end of surgery to prevent treat-
ment failure due to balloon displacement. 
A strength of our study is that we evaluated the effective-
ness of Bakri balloon particularly in massive bleeding among 
larger sample compared to previous studies since Bakri had 
been introduced. Among PPH patients, we analyzed women 
with estimated blood loss more than 1,500 mL. Our study 
also had homogeneity. All procedures were conducted by 
four obstetricians and the physician filled in the standardized 
Bakri insertion and removal records including causes of 
PPH, inflation volume of balloon, time of insertion and re­
moval and pain score. The major limitation of our study 
is the restrospective design that was restricted to evaluate 
complications or long term fertility. Another limitation is that 
there could have been a selection bias due to incomplete 
data in some of factors. In addition, women who underwent 
UAE or surgical procedure without trying to insert Bakri 
balloon were excluded in this study. It may affect to be 
overestimated the success rate of Bakri balloon in massive 
PPH. However, Bakri balloon could reduce heavy bleeding 
pending the arrangement of other procedures and this also 
regard efficiency of Bakri balloon to control massive PPH.
Intrauterine Bakri balloon tamponade is an effective tool 
with a comparable success rate to other treatment modalities 
for managing massive PPH when standard uterotonic agents 
fail. Considering its merits over other balloon catheters as 
well as its cost-effectiveness and lower invasiveness com-
pared to uterine artery embolization and hysterectomy, 
uterine balloon tamponade using the Bakri balloon catheter 
deserves to be the first choice among second-line therapies 
for patients with massive PPH who are unresponsive to 
uterotonic agents. In patients who were delivered by ce-
sarean section for placenta previa/accreta, intrauterine Bakri 
balloon combined with hemostatic compression sutures 
could further enhance success rates and preserve fertility. 
Bakri balloon tamponade can be also used not only in terti-
ary centers but also in limited-resource centers, and it may 
be able to earn time to prepare another procedure with pre-
venting massive bleeding or refer patient to another hospital. 
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